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Abstract
Background: The dystrobrevin-binding protein 1 (DTNBP1) gene is a susceptibility gene for
schizophrenia. There is growing evidence that DTNPB1 contributes to intelligence and cognition.
In this study, we investigated association between single nucleotide polymorphisms (SNPs) in the
DTNBP1 gene and intellectual functioning in patients with a first episode of schizophrenia or
related psychotic disorder (first-episode psychosis, FEP), their healthy siblings, and unrelated
controls.
Methods: From all subjects IQ measurements were obtained (verbal IQ [VIQ], performance IQ
[PIQ], and full scale IQ [FSIQ]). Seven SNPs in the DTNBP1 gene were genotyped using single base
primer extension and analyzed by matrix-assisted laser deionization mass spectrometry (MALDI-
TOF).
Results: Mean VIQ, PIQ, and FSIQ scores differed significantly (p < 0.001) between patients,
siblings, and controls. Using a family-based and a case-control design, several single SNPs were
significantly associated with IQ scores in patients, siblings, and controls.
Conclusion: Although preliminary, our results provide evidence for association between the
DTNBP1 gene and intelligence in patients with FEP and their unaffected siblings. Genetic variation
in the DTNBP1 gene may increase schizophrenia susceptibility by affecting intellectual functioning.
Background
Schizophrenia is associated with cognitive impairments
[1,2] as was already recognized by Kraepelin [3] who used
the term "dementia praecox" to describe a chronic, deteri-
orating psychotic disorder characterized by progressive
cognitive decline. To date, cognitive dysfunctions includ-
ing deficiencies in attention, working memory, and exec-
utive functions are considered core features of the clinical
schizophrenia phenotype, and are probably highly predic-
tive for functional outcome [4,5]. No single etiological
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substrate for schizophrenia and its associated cognitive
profile has yet been identified, but common abnormali-
ties include reductions in neuropil and size of neurons,
and structural and functional abnormalities of prefrontal
and temporal regions and the hippocampal formation
[6]. Also, altered glutamatergic neurotransmission has
been implicated as a functional substrate for psychotic
and cognitive symptoms in schizophrenia [7], in addition
to the classical dopamine hypothesis [8]. Evidence from
genetic linkage and association, and twin studies points to
a major contribution of genetic factors to schizophrenia
etiology [9]. Furthermore, since healthy family members
of patients with schizophrenia show similar cognitive def-
icits, the cognitive profile associated with schizophrenia is
probably highly heritable [10].
One of the key candidate genes to date is the dystrobrevin-
binding protein 1 (DTNBP1, or dysbindin) gene. Not only
have several genome scans reported linkage of chromo-
some 6p22–24 to schizophrenia [11-14], but also associ-
ation has been reported between schizophrenia and a set
of individual markers and haplotypes spanning the chro-
mosomal region containing the DTNBP1 gene (6p22.3), a
finding which has been replicated in several different pop-
ulations [15-24]. Despite the large number of studies sup-
porting DTBNP1 as a positional candidate gene for
schizophrenia [25], functional variants have not yet been
identified, nor have any pathophysiological mechanisms.
However, there is accumulating evidence that DTBNP1
may have a role in cognition. For example, one associa-
tion study found a specific protective haplotype that was
associated with higher educational achievement in
patients with schizophrenia [24]. The authors propose
that this protective haplotype within DTNBP1 may mod-
ify schizophrenia risk by enhancing cognition. This
hypothesis is supported by a recent genome scan for intel-
ligence using a large sample of healthy sib-pairs, that
revealed putative linkage on 6p25.3-6p22.3 [26], and by
a linkage scan in schizophrenia patients reporting linkage
at 6p24 to a neurocognitive deficit subtype of schizophre-
nia [27]. In addition, post-mortem studies have shown
that DTNBP1 expression is reduced in the hippocampus
and prefrontal cortex of patients with schizophrenia,
regions of the brain that are crucial for adequate cognitive
functioning [28]. DTNBP1 could also influence schizo-
phrenia liability and cognition by modulating glutamater-
gic or dopaminergic neurotransmission: DTNBP1 is
located in presynaptic glutamatergic neurons and is
reduced in patients with schizophrenia [29]; furthermore,
down-regulation of DTNBP1 may lead to hyperactivation
of midbrain dopaminergic systems [30]. Both the
dopaminergic and the glutamatergic systems are key neu-
rotransmitter systems for cognitive functioning [7,31].
Recent data from two independent groups further support
a role for DTNBP1 in cognition and schizophrenia suscep-
tibility. Burdick et al [32] recently reported association
between a DTNBP1 haplotype and general cognitive abil-
ity in patients with schizophrenia and in healthy controls.
Patients with schizophrenia carrying a DTNBP1 risk hap-
lotype previously identified by Funke [21], performed
worse on a neurocognitive test battery including the
Wechsler Adult Intelligence Test (WAIS) – Revised than
patients without the risk haplotype. Likewise, healthy
controls without the risk haplotype showed higher levels
of general cognitive ability than those carrying the risk
haplotype. Furthermore, a recent study by Donohoe et al
[33] reported that patients with schizophrenia carrying a
DTNBP1 risk haplotype showed impaired spatial working
memory performance in comparison to patients without
the risk haplotype. In addition to cognition, DTNBP1 has
recently been associated with high levels of negative
symptoms in patients with schizophrenia [34,35]; these
findings are relevant in this context since negative symp-
toms and cognitive dysfunction are highly correlated [36].
Given the evidence supporting DTNBP1 not only as a sus-
ceptibility gene for schizophrenia but also as a gene con-
tributing to intellectual functioning, we hypothesized that
variants in the DTNBP1 gene may contribute to the risk
for schizophrenia by affecting cognitive abilities. To date,
association between genetic variation in the DTNBP1
gene and intellectual functioning in unaffected relatives of
patients with schizophrenia-spectrum disorders has not
yet been studied. Therefore, we investigated association
between SNPs in the DTNBP1 gene and IQ in patients
with a first episode of schizophrenia or related psychotic
disorder (first-episode psychosis, FEP), their unaffected
siblings, and healthy controls.
Methods
Subjects and assessment
All patients were admitted to the Adolescent Clinic of the
Academic Medical Center of the University of Amsterdam
and attended a special program for adolescents with FEP.
After complete description of the study to the subjects,
written informed consent was obtained. The study was
approved by the human subjects review board of our insti-
tution. Exclusion criteria were organic brain disease,
endocrine disorder, or learning disability. Diagnosis was
established according to DSM-IV [37] criteria and was
based on the Mini International Neuropsychiatric Inter-
view (MINI) [38]. At time of testing patients were clini-
cally stable for at least four weeks (i.e. no changes in
antipsychotic medication in the four weeks before test-
ing). Additionally, healthy siblings were recruited, and
unrelated healthy controls from the general population
matched for age, educational level, and ethnicity. Both
groups were screened for psychopathology using the MINIBehavioral and Brain Functions 2007, 3:19 http://www.behavioralandbrainfunctions.com/content/3/1/19
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and were excluded when they had an Axis I disorder,
organic brain disease, or learning disability. All subjects
were administered the Wechsler Adult Intelligence Test –
third version (WAIS III). Blood was collected from all sub-
jects for DNA isolation. Where available, parents (of
patients) were asked to provide blood for DNA isolation.
DNA extraction and genetic analysis
Genomic DNA was extracted using a filter-based method
(QIAamp DNA Mini Kit, Qiagen Ltd, United Kingdom).
Genotyping was performed using single base primer
extension and analyzed by matrix-assisted laser-desorp-
tion/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) on a Bruker III Daltonics Mass Spec-
trometer as described previously [39] (details available
upon request). All DNA samples were genotyped in dupli-
cate to ensure reliability.
Choice of markers
We selected markers which showed association with
schizophrenia in previous studies. We chose 6 markers
(Table 1) from the original report by Straub [15]
(rs2619539, rs3213207, rs1011313, rs 2619528,
rs760761, and rs2619522) and 1 additional SNP first
reported by Williams [24] (rs2619538).
Statistical analysis
1. Demographics statistics
Differences in age and educational level between patients,
siblings and controls were analyzed using analysis of var-
iance (ANOVA), between-group differences in gender
were analyzed using χ2 tests. Differences in verbal IQ
(VIQ), performance IQ (PIQ), and full scale IQ (FSIQ)
scores between patients, siblings and controls were ana-
lyzed using ANOVA adjusting for age, gender, and educa-
tional level. The generalized estimating equations (GEE)
method [40] was used to correct for correlations due to
family relations. We used SAS version 9 (SAS Institute Inc.,
Cary NC, USA); level of statistical significance was defined
as p <0.05.
2. Association analysis with single SNPs and multiple SNP 
combinations in cases, siblings, and unrelated controls
Differences in allele frequencies between patients, sib-
lings, and controls were assessed using χ2  tests. We
assessed the effect of single SNPs in the DTNBP1 gene on
VIQ, PIQ, and FSIQ scores in patients with FEP, healthy
siblings, and unrelated controls using ANOVA adjusting
for age, gender, ethnicity, and educational level. The GEE
method was used to correct for possible correlations
between patients and siblings due to family relations. We
added the rare homozygotes to the heterozygotes, thus
analyzing 2 genotype groups instead of 3. Additionally,
association between VIQ, PIQ, and FSIQ, and multiple
SNP combinations was analyzed using backward stepwise
regression analysis as described previously, with all 7 pol-
ymorphisms in the initial model together with the (fixed)
covariates age, gender, ethnicity, and educational level.
Level of statistical significance was defined as p <0.05.
3. Quantitative pedigree disequilibrium test (QPDT)
In addition, we used a family-based analysis including
genotype data from patients, unaffected siblings, and par-
ents, to test for association between PIQ, VIQ, and FSIQ
scores and DTNBP1 polymorphisms. In total, 52 pedi-
grees were included in this analysis. All 52 pedigrees
included 1 proband, 26 pedigrees included 1 or more
unaffected siblings; in 26 pedigrees no unaffected sibling
was available. From 33/52 patients (63%) DNA from
both parents was available; from 19/52 patients (37%) we
had DNA from only one parent. Linkage disequilibrium
(LD) between SNPs was calculated in Haploview version
3.32 http://www.broad.mit.edu/mpg/haploview/
index.php with standard transmission disequilibrium test
(TDT) settings and expressed as D' and r2 (see Table 2). We
used the quantitative pedigree disequilibrium test
(QPDT) [41] implemented in UNPHASED [42]http://
www.mrc-bsu.cam.ac.uk/personal/frank/software/
unphased.
Rare marker combinations with frequencies below 0.05
were excluded from the analysis. Global p-values were
obtained for single SNPs and for 2-, 3- and 4- marker com-
binations in a sliding window.
Results
1. Demographic data
We included 76 patients with FEP, 31 healthy siblings,
and 31 unrelated control subjects (see Table 3). Ethnicity
counts are shown in Table 4. The patients met DSM-IV cri-
teria for schizophrenia (N = 57; 75%), schizoaffective dis-
order (N = 13; 17%), brief psychotic disorder (N = 3; 4%),
and psychotic disorder not otherwise specified (N = 3;
4%). Mean duration of psychosis was 20 months (SD =
15.06). Patients were receiving antipsychotic medication
(80.2%), mostly atypical antipsychotics. Mean dose of
antipsychotic medication in chlorpromazine equivalents
was 291.06 (SD = 266.70). Six out of 76 patients (8%)
were also diagnosed with mild to moderate depressive
disorder and used an SSRI. None of the healthy siblings
and none of the unrelated controls used any psychotropic
medication. Means and numbers for age, educational
level, gender, VIQ, PIQ, and FSIQ for cases, siblings and
controls are presented in Table 3. All data were normally
distributed. There was no difference between patients
receiving typical and atypical neuroleptic treatment on IQ
scores. We found no significant correlation between chlo-
rpromazine equivalents and FSIQ (Pearson's Rho=-0.13; p
= 0.3). Also, educational level did not differ significantly
between patients, siblings and controls (p = 0.11). TheBehavioral and Brain Functions 2007, 3:19 http://www.behavioralandbrainfunctions.com/content/3/1/19
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number of males and females differed significantly
between groups (p  <0.01). Mean VIQ, PIQ, and FSIQ
scores differed significantly (p <0.001) between patients,
siblings, and controls (Figure 1). IQ scores in patients
(mean VIQ = 89.2 ± 14.3, mean PIQ = 85.7 ± 13.0, mean
FSIQ = 86.7 ± 13.8) were significantly lower than IQ
scores in siblings (mean VIQ = 95.7 ± 11.1, mean PIQ =
98.6 ± 11.4, mean FSIQ = 96.7 ± 11.6) and controls
(mean VIQ = 105.6 ± 16.9, mean PIQ = 106.4 ± 14.4,
mean FSIQ = 107.0 ± 15.5). Post-hoc analyses showed
that siblings had significantly lower IQ scores than con-
trols (p = 0.005) and significantly higher IQ scores than
patients (p = 0.001) (Figure 1).
2. Association analysis with single SNPs and marker 
combinations in cases, siblings, and unrelated controls
None of the SNPs deviated from Hardy-Weinberg equilib-
rium. Allele frequencies did not differ between probands,
siblings and healthy controls (data not shown). After
adjusting for age, gender, ethnicity, educational level, and
family membership, 3 of the 7 SNPs examined (rs760761,
rs2619522, and rs2619538) showed significant associa-
tion with FSIQ scores in patients, siblings and controls
(rs760761: p = 0.026; rs2619522: p = 0.025; rs2619538: p
= 0.038; Table 5). Two SNPs showed association with
VIQ, a third showed marginal significance (rs760761: p =
0.049; rs2619522: p = 0.052; rs2619538: p = 0.029). Fur-
thermore, rs760761 and rs2619522 showed significant
association with PIQ (p-values 0.038 and 0.023 respec-
tively). Using non-parametric techniques (rank-transfor-
mation) similar p-values were obtained (data not shown).
When we analyzed association between IQ scores and 2-,
3-, or 4-marker combinations, none of the marker combi-
nations showed significant association with VIQ, PIQ, or
FSIQ scores (data not shown). The multiple SNP models
showed that a model including only rs760761 fitted the
data equally well compared to a model including all 7
SNPs, suggesting that the observed differences may be
caused by a single mutation.
3. QPDT results
We found significant association between FSIQ scores and
4 single SNPs in the DTNBP1 gene using the QPDT (rs
2619528: p = 0.044; rs 760761: p = 0.022; rs 2619522: p =
0.022; rs 2619538: p = 0.026). None of the 2-, 3-, or 4-
marker combinations showed significant association with
FSIQ scores. Three single SNPs showed significant associ-
ation with VIQ (rs760761: p  = 0.027; rs2619522: p  =
0.027; rs2619538: p = 0.030). The 4 SNPs associated with
FSIQ were also associated with PIQ (rs2619528: p  =
0.033; rs760761: p  = 0.023; rs2619522: p  = 0.024;
Table 1: SNP information
Inter marker distance Nucleotide change Minor allele frequency SNP description 
Ensembl release 42
Chr 6. position March 
2006 UCSC freeze
rs2619539 0 G/C 0.47 Intron 5 15728834
rs3213207 7247 A/G 0.13 Intron 4 15736081
rs1011313 5330 G/A 0.06 Intron 4 15741411
rs2619528 16397 G/A 0.30 Intron 3 15757808
rs760761 1303 C/T 0.28 Intron 3 15759111
rs2619522 2517 T/G 0.30 Intron 1 15761628
rs2619538 11560 A/T 0.49 5' flanking region 15773188
In the 3nd column ("nucleotide change") the common allele is presented first. Minor allele frequency in patients is given in the 3rd column.
SNP: Single Nucleotide Polymorphism. UCSC: University of California Santa Cruz, Genome Bioinformatics, http://genome.ucsc.edu/
http://www.ensembl.org/
Table 2: Pairwise LD in DTNBP1 polymorphisms
rs2619539 rs3213207 rs1011313 rs2619528 rs760761 rs2619522 rs2619538
rs2619539 - 0.156 0.111 0.0 0.0 0.001 0.055
rs3213207 1.0 - 0.014 0.334 0.403 0.34 0.076
rs1011313 0.916 1.0 - 0.037 0.033 0.036 0.081
rs2619528 0.024 0.955 1.0 - 0.838 0.737 0.128
rs760761 0.015 1 1.0 0.96 - 0.854 0.166
rs2619522 0.04 0.955 1.0 0.867 0.96 - 0.182
rs2619538 0.242 0.823 0.825 0.648 0.772 0.778 -
D' values and r2 values for all combinations of the 7 SNPs included in this study are calculated in Haploview version 3.32
http://www.broad.mit.edu/mpg/haploview/index.php with standard TDT settings.
Above diagonal r2-values are shown, below diagonal D'- values are shown.Behavioral and Brain Functions 2007, 3:19 http://www.behavioralandbrainfunctions.com/content/3/1/19
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rs2619538: p = 0.023). Using UNPHASED, we found LD
between the 4 SNPs associated with FSIQ to be high (D'
ranging from 0.7–1.0), therefore we think the SNPs are
part of an LD block and do not contribute to variance in
FSIQ individually.
Discussion
In our study population we found significant association
between single SNPs in the DTNBP1 gene and IQ meas-
urements in patients with FEP, their unaffected siblings,
and controls matched for age, educational level, and eth-
nicity. Rs760761 showed the strongest and most consist-
ent association with IQ values in patients, unaffected
siblings, and unrelated controls. Whether this association
is caused by rs760761 itself or by a functional mutation in
LD with this polymorphism, cannot be concluded from
our data.
Previous work on DTNBP1 and cognition
Our data are partly consistent with a recent report of asso-
ciation between genetic variation in DTNBP1 and meas-
ures of prefrontal brain function in healthy adults [43]. In
this study the polymorphisms rs2619528 and rs760761
showed strong association with prefrontal electrophysiol-
ogy as measured by event-related potentials (ERPs) both
individually and as part of a haplotype. In particular the
GG variant of rs2619528 and the CC variant of rs760761
were associated with impaired prefrontal brain electro-
physiology. In our study population, the rs760761 CC
genotype was associated with better intellectual function-
ing. A possible explanation for this discrepancy is that
genetic variation in DTNBP1 may differentially affect elec-
trophysiology and IQ measures. Alternatively, effects of
rs760761 on prefrontal brain electrophysiology in
healthy controls may differ from those in patients with
schizophrenia; therefore future studies should investigate
whether associations between DTNBP1 and electrophysi-
ological measures are also present in patients with schizo-
phrenia.
Support for a role of DTNBP1 in cognition and in schizo-
phrenia came first from Burdick [32] who recently
reported association between a DTNBP1 haplotype and
general cognitive ability, and from Donohoe et al [33]
who reported association between a DTNBP1 haplotype
and spatial working memory in patients with schizophre-
nia. Our data are consistent with these studies although
we used a different approach. The risk haplotype used by
Donohoe et al [33] was previously identified in same
cohort by Williams et al [24]; similarly, the risk haplotype
used by Burdick et al [32,44] and by DeRosse et al [35]
was previously identified in same sample by Funke et al
[21]. We however tested SNPs in a hypothesis-free fash-
ion. Also, the SNPs we typed did not include the tagging
SNP (rs1018381) from the risk haplotype used in the
sample of Funke et al [21]. And although we did type the
three SNPs that formed the risk haplotype in the Donohoe
et al [33] study, our study focused on general cognitive
ability similar to Burdick et al [32], whereas Donohoe
[33] investigated a specific cognitive process, namely spa-
Table 3: Subject characteristics
Patients N = 76 Siblings N = 31 Controls N = 31 Statistic p-value
Age (SD) 21.5 (2.9) 22.8 (3.8) 21.5 (3.1) F = 2.27 p = 0.11
Gender (M/F) 66/10 13/18 23/8 χ2 = 23.03 p <0.001
Educational level (SD) 4.45 (0.91) 4.76 (1.15) 4.83 (1.09) F = 1.94 p = 0.15
VIQ (SD) 89.2 (14.3) 95.7 (11.1) 105.6 (16.9) F = 14.68 p <0.001*
PIQ (SD) 85.7 (13.0) 98.6 (11.4) 106.4 (14.4) F = 31.35 p <0.001*
FSIQ (SD) 86.7 (13.8) 96.7 (11.6) 107.0 (15.5) F = 25.12 p <0.001*
Subject characteristics (age, gender, and educational level) and verbal, performance, and full scale IQ scores (VIQ, PIQ, and FSIQ). Between-group 
differences in age, educational level, and between VIQ, PIQ, and FSIQ are calculated using ANOVA. Between-group differences in gender are 
calculated using a χ2 test. The p-values marked with * result from an overall ANOVA; all pairwise comparisons are significant.
Table 4: Overview of subjects' countries of origin
Subject
Country of origin Patients Siblings Controls
Netherlands (white Caucasian) 48 25 22
Turkey 3 1 0
Morocco 4 0 4
Surinam or Dutch Antilles 17 3 5
Missing 4 2 0
Country of origin did not differ significantly between subject groups (Fisher's Exact = 9.44, p = 0.24).Behavioral and Brain Functions 2007, 3:19 http://www.behavioralandbrainfunctions.com/content/3/1/19
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tial working memory. Therefore, results may be partly dis-
crepant from previous studies due to differences in
approach, cognitive measures, and genotyped SNPs.
Biological mechanism
Our data add to the growing evidence that genetic varia-
tion in the DTNBP1 gene modifies schizophrenia suscep-
tibility by influencing general cognitive abilities. Not only
is the 6p22–24 locus implicated in cognition and neuro-
cognitive deficit in schizophrenia by recent genome scans
[26,27] and has DTNBP1 been associated with more
severe negative symptoms which are highly correlated to
cognitive dysfunction [34,45], but also recent neu-
ropathological studies have revealed reduced expression
of DTNBP1 in the prefrontal cortex [28] and in the hip-
pocampus [29] in postmortem brain tissue of schizophre-
nia patients. Both structures are involved in cognitive
functions, the prefrontal cortex merely in working mem-
ory and executive function, the hippocampus mainly in
memory formation. Also, risk haplotypes in the DTNBP1
gene have been associated with reduced expression of
DTNBP1 mRNA in brain tissue of healthy subjects and in
patients with schizophrenia, whereas 'protective' haplo-
types were associated with high DTNBP1 expression [46].
Changes in DTNBP1 expression are probably not caused
by antipsychotic drug treatment [47] but instead may
reflect an increased genetic vulnerability for schizophre-
nia. Thus, genetic variation in the DTNBP1 gene may
modulate schizophrenia susceptibility by altering
DTNBP1 expression in areas of the brain crucial for cogni-
tive functions. This may occur already in an early stage,
since genetic variation in DTNBP1 has been associated
with poor premorbid function in children developing
childhood-onset schizophrenia [48], suggesting that
DTNBP1 contributes to early neurodevelopmental
impairment. A possible mechanism by which dysbindin
contributes to schizophrenia susceptibility, may be by
modulating neurotransmitter systems in regions of the
brain that are crucial for cognitive functioning and that
are probably disturbed in schizophrenia: the glutamater-
gic system in the hippocampal formation and the
dopaminergic system in the prefrontal cortex.
Table 5: Mean IQ values and associations by SNP and genotype
Mean FSIQ (SD)
Non-carriers Carriers Z-statistic Adjusted p-value
rs 2619539 91.02 (16.02) 94.52 (15.92) 1.02 0.308
rs 3213207 94.16 (15.96) 91.30 (16.06) -1.60 0.109
rs 1011313 93.50 (16.37) 93.29 (13.23) 1.29 0.198
rs 2619528 96.36 (15.21) 89.95 (16.30) -1.65 0.098
rs 760761 96.79 (15.18) 88.77 (16.02) -2.23 0.026
rs 2619522 96.74 (15.29) 89.23 (15.97) -2.25 0.025
rs 2619538 88.52 (16.57) 95.04 (15.54) 2.08 0.038
Observed mean FSIQ values of the total population (patients, siblings and controls) with standard deviation (SD) are given in 'carriers' versus the 
'non-carriers' in which 'carriers' represent the carriers of the low-frequency allele. P-values are given for the comparison of FSIQ values between 
genotype groups (carriers and non-carriers) using ANOVA with GEE adjusting for age, gender, ethnicity, family membership, and educational level.
Mean FSIQ in patients, siblings and controls Figure 1
Mean FSIQ in patients, siblings and controls. Distribu-
tion of FSIQ by genotype within each subject group for the 
most consistently associated SNP (rs760761) is shown. In the 
whole group, FSIQ scores in patients with FEP (mean = 86.7, 
SEM = 1.58) were significantly lower than IQ scores in sib-
lings (mean = 96.7, SEM = 2.08) and controls (mean = 107.0, 
SEM = 2.79) (ANOVA adjusting for age, gender, and educa-
tional level, p < 0.001). Post-hoc analyses showed that sib-
lings had significantly higher IQ scores than patients (* p = 
0.001) and significantly lower IQ scores than controls (** p = 
0.005).Behavioral and Brain Functions 2007, 3:19 http://www.behavioralandbrainfunctions.com/content/3/1/19
Page 7 of 10
(page number not for citation purposes)
Recently, Talbot [29] investigated expression and localiza-
tion of DTNBP1 in postmortem brain tissue of schizo-
phrenia patients and reported evidence for a relationship
between DTNBP1 and hippocampal glutamate neuro-
transmission: DTNBP1 expression was reduced in termi-
nal fields of intrinsic glutamatergic connections and these
reductions were related to glutamatergic alterations in
intrinsic hippocampal formation connections [29]. Gluta-
matergic neurotransmission in the hippocampus is
important for memory formation [49], therefore reduc-
tions in DTNBP1 in the hippocampus of schizophrenia
patients as observed by Talbot [29] may disturb normal
information processing and diminish synaptic plasticity
in the hippocampus. The hippocampus has been impli-
cated in schizophrenia pathogenesis previously, both by
structural neuroimaging studies reporting reductions of
hippocampal size, and by neuropathological studies
reporting abnormal clustering of neurons [50,51].
Another possible mechanism by which DTNBP1 could
modulate schizophrenia susceptibility, is by modulating
prefrontal cortex (PFC) function. Reduced DTNBP1
expression has been reported in the dorsolateral PFC
(DLPFC) in postmortem brain tissue of patients with
schizophrenia [28]. Disturbed development of the DLPFC
probably underlies cognitive dysfunction in schizophre-
nia and may contribute to schizophrenia pathogenesis
[52]. Recently Kumamoto et al [30] reported that
DTNBP1 also may be involved in the dopaminergic sys-
tem, and may be capable of activating the midbrain
dopaminergic system via indirect pathways [30].
Dopaminergic systems in the PFC and midbrain form a
feedback mechanism and are modulated by genetic varia-
tion in dopamine clearance pathways; tuning of these sys-
tems is of critical importance for optimal cognitive
functioning [53-56]. Thus, genetic variation in DTNBP1
may impact on dopaminergic and glutamatergic systems
in the PFC and hippocampus, thereby disturbing memory
and cognition and increasing schizophrenia susceptibil-
ity.
Strengths and limitations
Strength of our study is the relatively young age of the
patients (mean age was 21 years in our sample versus
approximately 40 years in the sample of Burdick et al
[32]), therefore potential confounders, e.g. disease dura-
tion or chronic antipsychotic treatment, are unlikely to
influence IQ measurements. Limitations of our study are
small sample size and the use of an ethnically mixed sam-
ple. To reduce the risk for population stratification, we (1)
adjusted for ethnicity in the case-control analyses; (2)
used unaffected siblings as controls; (3) matched the
unrelated controls for ethnicity; and (4) used additional
family-based analyses which confirmed results of the case-
control analyses. Therefore, we think it is unlikely our
results are due to admixture. Multiple testing effects could
also allow the occurrence of type I errors. Because we
expect the contribution of individual genes to the risk of
complex genetic disorders to be small, and because the
tests we performed are not completely independent (LD
between SNPs is high and VIQ, PIQ, and FSIQ are highly
correlated) we consider the Bonferroni method too strict
to correct for type I error. However, we acknowledge that
our results would not survive other – less stringent –
methods to correct for multiple testing. Therefore our
findings are preliminary and need to be replicated in a
large and genetically homogeneous sample. Also, most of
our included patients are male; therefore results may not
generalize to female patients. Finally, although we found
no correlation between chlorpromazine equivalents and
FSIQ, the use of antipsychotic medication is a potential
confounding factor in our study since all patients used
antipsychotics whereas neither the siblings nor the unre-
lated controls used any psychotropic medication.
Future directions
Future research will need to further investigate the com-
plex genetic background of cognitive phenotypes in schiz-
ophrenia, including involvement of multiple
susceptibility genes and gene-environmental interactions.
Additionally, the use of combined techniques for measur-
ing cognitive phenotypes, e.g. acquiring functional brain
images during neuropsychological testing, may improve
reliability and resolution of cognitive phenotypes in
schizophrenia, thereby increasing power for molecular
genetic studies.
Conclusion
In this study, we report association between genetic varia-
tion in the DTNBP1 gene and IQ measures in patients
with first-episode psychosis, unaffected siblings, and
unrelated control subjects. There is growing evidence that
genetic variation modulates cognition in schizophrenia;
not only has genetic variation in DTNBP1 previously been
associated with spatial working memory function and
general intellectual function [32,33], but also variations
in the DISC 1 gene have been related to structure and
function of the hippocampus [57], and a functional vari-
ant in the NRG1 gene has been associated with impaired
prefrontal function and decreased IQ [58]. Although pre-
liminary, our results add to the growing body of research
that genetic variation in DTNBP1 alters schizophrenia lia-
bility, possibly by affecting cognition.
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